nodes	percent_of_prediction	percent_of_DWPC	metapath
Zidovudine—acquired immunodeficiency syndrome—sarcoma	0.657	1	CtDrD
Zidovudine—UGT2B7—Epirubicin—sarcoma	0.0438	0.203	CbGbCtD
Zidovudine—ABCG2—Dactinomycin—sarcoma	0.0287	0.133	CbGbCtD
Zidovudine—ABCG2—Mitoxantrone—sarcoma	0.0257	0.119	CbGbCtD
Zidovudine—ABCG2—Vincristine—sarcoma	0.0177	0.082	CbGbCtD
Zidovudine—ABCG2—Etoposide—sarcoma	0.0162	0.0751	CbGbCtD
Zidovudine—CYP3A4—Thiotepa—sarcoma	0.0129	0.0599	CbGbCtD
Zidovudine—ABCG2—Doxorubicin—sarcoma	0.0111	0.0512	CbGbCtD
Zidovudine—ABCB1—Dactinomycin—sarcoma	0.0104	0.048	CbGbCtD
Zidovudine—ABCB1—Mitoxantrone—sarcoma	0.00927	0.043	CbGbCtD
Zidovudine—CYP2C8—Etoposide—sarcoma	0.00863	0.04	CbGbCtD
Zidovudine—ABCB1—Vincristine—sarcoma	0.00638	0.0296	CbGbCtD
Zidovudine—ABCB1—Etoposide—sarcoma	0.00584	0.0271	CbGbCtD
Zidovudine—CYP3A4—Mitoxantrone—sarcoma	0.00555	0.0257	CbGbCtD
Zidovudine—ABCB1—Doxorubicin—sarcoma	0.00399	0.0185	CbGbCtD
Zidovudine—CYP3A4—Vincristine—sarcoma	0.00382	0.0177	CbGbCtD
Zidovudine—CYP3A4—Etoposide—sarcoma	0.0035	0.0162	CbGbCtD
Zidovudine—CYP3A4—Doxorubicin—sarcoma	0.00239	0.0111	CbGbCtD
Zidovudine—TERT—embryo—sarcoma	0.00152	0.0565	CbGeAlD
Zidovudine—TERT—hematopoietic system—sarcoma	0.00136	0.0504	CbGeAlD
Zidovudine—TERT—connective tissue—sarcoma	0.00131	0.0486	CbGeAlD
Zidovudine—TERT—skin of body—sarcoma	0.00118	0.0438	CbGeAlD
Zidovudine—TERT—uterus—sarcoma	0.00103	0.0381	CbGeAlD
Zidovudine—TERT—lymphoid tissue—sarcoma	0.000956	0.0355	CbGeAlD
Zidovudine—TK1—hematopoietic system—sarcoma	0.000934	0.0347	CbGeAlD
Zidovudine—TK1—skin of body—sarcoma	0.000812	0.0302	CbGeAlD
Zidovudine—TERT—testis—sarcoma	0.000744	0.0276	CbGeAlD
Zidovudine—SLC28A1—liver—sarcoma	0.000717	0.0266	CbGeAlD
Zidovudine—TK1—uterus—sarcoma	0.000706	0.0262	CbGeAlD
Zidovudine—TERT—liver—sarcoma	0.000703	0.0261	CbGeAlD
Zidovudine—ABCC5—mammary gland—sarcoma	0.000685	0.0254	CbGeAlD
Zidovudine—TK1—lymphoid tissue—sarcoma	0.000658	0.0244	CbGeAlD
Zidovudine—TK1—tendon—sarcoma	0.000618	0.023	CbGeAlD
Zidovudine—TK1—bone marrow—sarcoma	0.000599	0.0222	CbGeAlD
Zidovudine—SLC29A2—cardiac atrium—sarcoma	0.000587	0.0218	CbGeAlD
Zidovudine—TK1—testis—sarcoma	0.000512	0.019	CbGeAlD
Zidovudine—SLC29A2—tendon—sarcoma	0.000511	0.019	CbGeAlD
Zidovudine—ALB—mammary gland—sarcoma	0.00049	0.0182	CbGeAlD
Zidovudine—SLC29A2—liver—sarcoma	0.0004	0.0149	CbGeAlD
Zidovudine—CYP2A6—seminal vesicle—sarcoma	0.000394	0.0146	CbGeAlD
Zidovudine—TK1—lymph node—sarcoma	0.000371	0.0138	CbGeAlD
Zidovudine—CYP2C8—mammary gland—sarcoma	0.000345	0.0128	CbGeAlD
Zidovudine—ABCC5—cardiac atrium—sarcoma	0.000317	0.0118	CbGeAlD
Zidovudine—SLC29A2—lymph node—sarcoma	0.000307	0.0114	CbGeAlD
Zidovudine—CYP2C9—mammary gland—sarcoma	0.000306	0.0114	CbGeAlD
Zidovudine—ABCC4—hematopoietic system—sarcoma	0.000289	0.0107	CbGeAlD
Zidovudine—SLC22A8—hematopoietic system—sarcoma	0.000287	0.0107	CbGeAlD
Zidovudine—UGT2B7—testis—sarcoma	0.000286	0.0106	CbGeAlD
Zidovudine—ABCC5—tendon—sarcoma	0.000276	0.0103	CbGeAlD
Zidovudine—SLC22A7—testis—sarcoma	0.000272	0.0101	CbGeAlD
Zidovudine—UGT2B7—liver—sarcoma	0.00027	0.01	CbGeAlD
Zidovudine—ABCC5—bone marrow—sarcoma	0.000268	0.00994	CbGeAlD
Zidovudine—SLC22A11—liver—sarcoma	0.000264	0.00979	CbGeAlD
Zidovudine—SLC22A7—liver—sarcoma	0.000257	0.00955	CbGeAlD
Zidovudine—ABCC4—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000241	0.0109	CbGpPWpGaD
Zidovudine—CYP2C19—hematopoietic system—sarcoma	0.000241	0.00894	CbGeAlD
Zidovudine—ABCG2—myometrium—sarcoma	0.000238	0.00883	CbGeAlD
Zidovudine—TERT—IL2 signaling events mediated by PI3K—MYC—sarcoma	0.000233	0.0106	CbGpPWpGaD
Zidovudine—TK1—Fluoropyrimidine Activity—TP53—sarcoma	0.000232	0.0105	CbGpPWpGaD
Zidovudine—ABCC5—testis—sarcoma	0.000229	0.00849	CbGeAlD
Zidovudine—ABCC4—uterus—sarcoma	0.000219	0.00812	CbGeAlD
Zidovudine—ABCC5—liver—sarcoma	0.000216	0.00803	CbGeAlD
Zidovudine—ABCG2—seminal vesicle—sarcoma	0.000215	0.00798	CbGeAlD
Zidovudine—ABCC4—Ectoderm Differentiation—PAX3—sarcoma	0.000214	0.00972	CbGpPWpGaD
Zidovudine—TERT—Signaling by Wnt—TLE1—sarcoma	0.000212	0.00963	CbGpPWpGaD
Zidovudine—CYP2C8—hematopoietic system—sarcoma	0.00021	0.0078	CbGeAlD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	0.000202	0.0092	CbGpPWpGaD
Zidovudine—CYP2A6—liver—sarcoma	0.000194	0.0072	CbGeAlD
Zidovudine—ABCC4—tendon—sarcoma	0.000191	0.00711	CbGeAlD
Zidovudine—ABCG2—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.000191	0.00867	CbGpPWpGaD
Zidovudine—CYP2C9—hematopoietic system—sarcoma	0.000187	0.00693	CbGeAlD
Zidovudine—ABCC4—bone marrow—sarcoma	0.000185	0.00689	CbGeAlD
Zidovudine—TERT—Regulation of Telomerase—IL2—sarcoma	0.000183	0.00832	CbGpPWpGaD
Zidovudine—TERT—HIF-1-alpha transcription factor network—JUN—sarcoma	0.000182	0.00829	CbGpPWpGaD
Zidovudine—TERT—Regulation of Telomerase—CCND1—sarcoma	0.000178	0.00811	CbGpPWpGaD
Zidovudine—TERT—Regulation of Telomerase—JUN—sarcoma	0.000178	0.00809	CbGpPWpGaD
Zidovudine—ABCG2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000177	0.00803	CbGpPWpGaD
Zidovudine—ABCC5—lymph node—sarcoma	0.000166	0.00616	CbGeAlD
Zidovudine—ABCC4—Platelet degranulation—VEGFC—sarcoma	0.000164	0.00746	CbGpPWpGaD
Zidovudine—ALB—testis—sarcoma	0.000164	0.00608	CbGeAlD
Zidovudine—CYP2A6—Fluoropyrimidine Activity—SMUG1—sarcoma	0.00016	0.00729	CbGpPWpGaD
Zidovudine—TERT—HIF-1-alpha transcription factor network—VEGFA—sarcoma	0.000159	0.00724	CbGpPWpGaD
Zidovudine—ABCC4—testis—sarcoma	0.000159	0.00589	CbGeAlD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.000157	0.00712	CbGpPWpGaD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.000156	0.00711	CbGpPWpGaD
Zidovudine—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	0.000156	0.0071	CbGpPWpGaD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.000155	0.00705	CbGpPWpGaD
Zidovudine—ALB—liver—sarcoma	0.000155	0.00575	CbGeAlD
Zidovudine—ABCG2—uterus—sarcoma	0.000154	0.00573	CbGeAlD
Zidovudine—ABCG2—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.00015	0.00682	CbGpPWpGaD
Zidovudine—ABCC4—liver—sarcoma	0.00015	0.00557	CbGeAlD
Zidovudine—TK1—E2F transcription factor network—MYC—sarcoma	0.00015	0.0068	CbGpPWpGaD
Zidovudine—TERT—formation of the beta-catenin:TCF transactivating complex—CTNNB1—sarcoma	0.000145	0.00659	CbGpPWpGaD
Zidovudine—TERT—Cell Cycle—STAG1—sarcoma	0.000145	0.00657	CbGpPWpGaD
Zidovudine—TERT—Regulation of Telomerase—MYC—sarcoma	0.000143	0.00651	CbGpPWpGaD
Zidovudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000142	0.00647	CbGpPWpGaD
Zidovudine—CYP3A4—hematopoietic system—sarcoma	0.000142	0.00528	CbGeAlD
Zidovudine—TK1—Validated targets of C-MYC transcriptional activation—MYC—sarcoma	0.00014	0.00638	CbGpPWpGaD
Zidovudine—TERT—Regulation of Telomerase—EGFR—sarcoma	0.00014	0.00636	CbGpPWpGaD
Zidovudine—ABCG2—bone marrow—sarcoma	0.000131	0.00486	CbGeAlD
Zidovudine—TERT—Validated targets of C-MYC transcriptional activation—MYC—sarcoma	0.000127	0.00577	CbGpPWpGaD
Zidovudine—CYP2A6—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000127	0.00577	CbGpPWpGaD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	0.000126	0.00571	CbGpPWpGaD
Zidovudine—CYP2C19—liver—sarcoma	0.000125	0.00463	CbGeAlD
Zidovudine—TERT—Cell Cycle—NPM1—sarcoma	0.000124	0.00564	CbGpPWpGaD
Zidovudine—ALB—lymph node—sarcoma	0.000119	0.00441	CbGeAlD
Zidovudine—TERT—formation of the beta-catenin:TCF transactivating complex—MYC—sarcoma	0.000118	0.00534	CbGpPWpGaD
Zidovudine—ABCB1—myometrium—sarcoma	0.000117	0.00436	CbGeAlD
Zidovudine—ALB—Binding and Uptake of Ligands by Scavenger Receptors—HBA1—sarcoma	0.000117	0.0053	CbGpPWpGaD
Zidovudine—TK1—Validated targets of C-MYC transcriptional activation—TP53—sarcoma	0.000115	0.00524	CbGpPWpGaD
Zidovudine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.000115	0.00524	CbGpPWpGaD
Zidovudine—CYP2C8—testis—sarcoma	0.000115	0.00427	CbGeAlD
Zidovudine—ABCC4—lymph node—sarcoma	0.000115	0.00427	CbGeAlD
Zidovudine—ABCB1—embryo—sarcoma	0.000113	0.00419	CbGeAlD
Zidovudine—ABCG2—testis—sarcoma	0.000112	0.00416	CbGeAlD
Zidovudine—ABCG2—HIF-2-alpha transcription factor network—KDR—sarcoma	0.00011	0.005	CbGpPWpGaD
Zidovudine—CYP2C8—liver—sarcoma	0.000109	0.00404	CbGeAlD
Zidovudine—ABCB1—seminal vesicle—sarcoma	0.000106	0.00393	CbGeAlD
Zidovudine—ABCG2—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000106	0.00481	CbGpPWpGaD
Zidovudine—ABCG2—liver—sarcoma	0.000106	0.00393	CbGeAlD
Zidovudine—TERT—TGF-beta Signaling Pathway—CCND1—sarcoma	0.000105	0.00477	CbGpPWpGaD
Zidovudine—TERT—TGF-beta Signaling Pathway—JUN—sarcoma	0.000105	0.00476	CbGpPWpGaD
Zidovudine—TERT—Validated targets of C-MYC transcriptional activation—TP53—sarcoma	0.000104	0.00474	CbGpPWpGaD
Zidovudine—ABCB1—hematopoietic system—sarcoma	0.000101	0.00374	CbGeAlD
Zidovudine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.000101	0.00457	CbGpPWpGaD
Zidovudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	9.91e-05	0.0045	CbGpPWpGaD
Zidovudine—ALB—Vitamin B12 Metabolism—HBA1—sarcoma	9.79e-05	0.00445	CbGpPWpGaD
Zidovudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	9.76e-05	0.00443	CbGpPWpGaD
Zidovudine—CYP2C9—liver—sarcoma	9.66e-05	0.00359	CbGeAlD
Zidovudine—TERT—TGF-beta Signaling Pathway—SRC—sarcoma	9.39e-05	0.00427	CbGpPWpGaD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	9.32e-05	0.00119	CcSEcCtD
Zidovudine—Discomfort—Etoposide—sarcoma	9.27e-05	0.00119	CcSEcCtD
Zidovudine—Breast disorder—Epirubicin—sarcoma	9.27e-05	0.00119	CcSEcCtD
Zidovudine—Pain—Mitoxantrone—sarcoma	9.25e-05	0.00119	CcSEcCtD
Zidovudine—Constipation—Mitoxantrone—sarcoma	9.25e-05	0.00119	CcSEcCtD
Zidovudine—Toxic epidermal necrolysis—Epirubicin—sarcoma	9.24e-05	0.00118	CcSEcCtD
Zidovudine—Aspartate aminotransferase increased—Epirubicin—sarcoma	9.24e-05	0.00118	CcSEcCtD
Zidovudine—ABCC5—Fluoropyrimidine Activity—TP53—sarcoma	9.23e-05	0.00419	CbGpPWpGaD
Zidovudine—Nasopharyngitis—Epirubicin—sarcoma	9.18e-05	0.00118	CcSEcCtD
Zidovudine—Gastrointestinal pain—Vincristine—sarcoma	9.08e-05	0.00116	CcSEcCtD
Zidovudine—Confusional state—Etoposide—sarcoma	9.07e-05	0.00116	CcSEcCtD
Zidovudine—Anaphylactic shock—Etoposide—sarcoma	9e-05	0.00115	CcSEcCtD
Zidovudine—Mood swings—Doxorubicin—sarcoma	9e-05	0.00115	CcSEcCtD
Zidovudine—Asthenia—Thiotepa—sarcoma	8.99e-05	0.00115	CcSEcCtD
Zidovudine—Asthenia—Dactinomycin—sarcoma	8.92e-05	0.00114	CcSEcCtD
Zidovudine—Feeling abnormal—Mitoxantrone—sarcoma	8.92e-05	0.00114	CcSEcCtD
Zidovudine—Influenza—Epirubicin—sarcoma	8.87e-05	0.00114	CcSEcCtD
Zidovudine—Dysphagia—Epirubicin—sarcoma	8.87e-05	0.00114	CcSEcCtD
Zidovudine—Pruritus—Thiotepa—sarcoma	8.86e-05	0.00114	CcSEcCtD
Zidovudine—Gastrointestinal pain—Mitoxantrone—sarcoma	8.85e-05	0.00113	CcSEcCtD
Zidovudine—Thrombocytopenia—Etoposide—sarcoma	8.81e-05	0.00113	CcSEcCtD
Zidovudine—Abdominal pain—Vincristine—sarcoma	8.78e-05	0.00113	CcSEcCtD
Zidovudine—Body temperature increased—Vincristine—sarcoma	8.78e-05	0.00113	CcSEcCtD
Zidovudine—Skin disorder—Etoposide—sarcoma	8.74e-05	0.00112	CcSEcCtD
Zidovudine—Hyperhidrosis—Etoposide—sarcoma	8.7e-05	0.00111	CcSEcCtD
Zidovudine—Pancreatitis—Epirubicin—sarcoma	8.7e-05	0.00111	CcSEcCtD
Zidovudine—Urticaria—Mitoxantrone—sarcoma	8.59e-05	0.0011	CcSEcCtD
Zidovudine—Breast disorder—Doxorubicin—sarcoma	8.58e-05	0.0011	CcSEcCtD
Zidovudine—Anorexia—Etoposide—sarcoma	8.58e-05	0.0011	CcSEcCtD
Zidovudine—Diarrhoea—Thiotepa—sarcoma	8.57e-05	0.0011	CcSEcCtD
Zidovudine—ABCC5—Carbohydrate metabolism—ENO2—sarcoma	8.56e-05	0.00389	CbGpPWpGaD
Zidovudine—Abdominal pain—Mitoxantrone—sarcoma	8.55e-05	0.0011	CcSEcCtD
Zidovudine—Body temperature increased—Mitoxantrone—sarcoma	8.55e-05	0.0011	CcSEcCtD
Zidovudine—Aspartate aminotransferase increased—Doxorubicin—sarcoma	8.55e-05	0.0011	CcSEcCtD
Zidovudine—Toxic epidermal necrolysis—Doxorubicin—sarcoma	8.55e-05	0.0011	CcSEcCtD
Zidovudine—Diarrhoea—Dactinomycin—sarcoma	8.51e-05	0.00109	CcSEcCtD
Zidovudine—Nasopharyngitis—Doxorubicin—sarcoma	8.49e-05	0.00109	CcSEcCtD
Zidovudine—Pancytopenia—Epirubicin—sarcoma	8.42e-05	0.00108	CcSEcCtD
Zidovudine—TERT—TGF-beta Signaling Pathway—MYC—sarcoma	8.42e-05	0.00383	CbGpPWpGaD
Zidovudine—CYP2C19—Melatonin metabolism and effects—FOXO1—sarcoma	8.37e-05	0.0038	CbGpPWpGaD
Zidovudine—Dysuria—Epirubicin—sarcoma	8.29e-05	0.00106	CcSEcCtD
Zidovudine—Neutropenia—Epirubicin—sarcoma	8.29e-05	0.00106	CcSEcCtD
Zidovudine—Dizziness—Thiotepa—sarcoma	8.28e-05	0.00106	CcSEcCtD
Zidovudine—Dysphagia—Doxorubicin—sarcoma	8.21e-05	0.00105	CcSEcCtD
Zidovudine—Influenza—Doxorubicin—sarcoma	8.21e-05	0.00105	CcSEcCtD
Zidovudine—Pollakiuria—Epirubicin—sarcoma	8.19e-05	0.00105	CcSEcCtD
Zidovudine—ABCG2—lymph node—sarcoma	8.11e-05	0.00301	CbGeAlD
Zidovudine—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	8.11e-05	0.00369	CbGpPWpGaD
Zidovudine—Paraesthesia—Etoposide—sarcoma	8.08e-05	0.00104	CcSEcCtD
Zidovudine—Pancreatitis—Doxorubicin—sarcoma	8.05e-05	0.00103	CcSEcCtD
Zidovudine—Weight decreased—Epirubicin—sarcoma	8.03e-05	0.00103	CcSEcCtD
Zidovudine—Dyspnoea—Etoposide—sarcoma	8.02e-05	0.00103	CcSEcCtD
Zidovudine—Somnolence—Etoposide—sarcoma	8e-05	0.00102	CcSEcCtD
Zidovudine—Asthenia—Vincristine—sarcoma	7.97e-05	0.00102	CcSEcCtD
Zidovudine—ALB—Folate Metabolism—HBA1—sarcoma	7.97e-05	0.00362	CbGpPWpGaD
Zidovudine—Vomiting—Thiotepa—sarcoma	7.97e-05	0.00102	CcSEcCtD
Zidovudine—SLC22A7—Fluoropyrimidine Activity—TP53—sarcoma	7.94e-05	0.00361	CbGpPWpGaD
Zidovudine—Vomiting—Dactinomycin—sarcoma	7.91e-05	0.00101	CcSEcCtD
Zidovudine—Rash—Thiotepa—sarcoma	7.9e-05	0.00101	CcSEcCtD
Zidovudine—Dermatitis—Thiotepa—sarcoma	7.89e-05	0.00101	CcSEcCtD
Zidovudine—Headache—Thiotepa—sarcoma	7.85e-05	0.00101	CcSEcCtD
Zidovudine—Stevens-Johnson syndrome—Epirubicin—sarcoma	7.84e-05	0.001	CcSEcCtD
Zidovudine—Rash—Dactinomycin—sarcoma	7.84e-05	0.001	CcSEcCtD
Zidovudine—Decreased appetite—Etoposide—sarcoma	7.82e-05	0.001	CcSEcCtD
Zidovudine—Pancytopenia—Doxorubicin—sarcoma	7.79e-05	0.000999	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Etoposide—sarcoma	7.77e-05	0.000995	CcSEcCtD
Zidovudine—Asthenia—Mitoxantrone—sarcoma	7.76e-05	0.000994	CcSEcCtD
Zidovudine—Fatigue—Etoposide—sarcoma	7.76e-05	0.000994	CcSEcCtD
Zidovudine—Neuropathy peripheral—Epirubicin—sarcoma	7.75e-05	0.000993	CcSEcCtD
Zidovudine—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.73e-05	0.00352	CbGpPWpGaD
Zidovudine—Stomatitis—Epirubicin—sarcoma	7.71e-05	0.000988	CcSEcCtD
Zidovudine—Jaundice—Epirubicin—sarcoma	7.71e-05	0.000988	CcSEcCtD
Zidovudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	7.7e-05	0.0035	CbGpPWpGaD
Zidovudine—Constipation—Etoposide—sarcoma	7.7e-05	0.000986	CcSEcCtD
Zidovudine—Pain—Etoposide—sarcoma	7.7e-05	0.000986	CcSEcCtD
Zidovudine—Dysuria—Doxorubicin—sarcoma	7.67e-05	0.000983	CcSEcCtD
Zidovudine—Neutropenia—Doxorubicin—sarcoma	7.67e-05	0.000983	CcSEcCtD
Zidovudine—ABCB1—uterus—sarcoma	7.61e-05	0.00282	CbGeAlD
Zidovudine—Diarrhoea—Vincristine—sarcoma	7.6e-05	0.000974	CcSEcCtD
Zidovudine—Sweating—Epirubicin—sarcoma	7.58e-05	0.000971	CcSEcCtD
Zidovudine—Pollakiuria—Doxorubicin—sarcoma	7.58e-05	0.000971	CcSEcCtD
Zidovudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	7.56e-05	0.00344	CbGpPWpGaD
Zidovudine—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.55e-05	0.00343	CbGpPWpGaD
Zidovudine—Haematuria—Epirubicin—sarcoma	7.54e-05	0.000966	CcSEcCtD
Zidovudine—Hepatobiliary disease—Epirubicin—sarcoma	7.48e-05	0.000958	CcSEcCtD
Zidovudine—Epistaxis—Epirubicin—sarcoma	7.46e-05	0.000956	CcSEcCtD
Zidovudine—Nausea—Thiotepa—sarcoma	7.44e-05	0.000953	CcSEcCtD
Zidovudine—Weight decreased—Doxorubicin—sarcoma	7.43e-05	0.000951	CcSEcCtD
Zidovudine—ALB—Platelet degranulation—VEGFC—sarcoma	7.42e-05	0.00337	CbGpPWpGaD
Zidovudine—Sinusitis—Epirubicin—sarcoma	7.42e-05	0.000951	CcSEcCtD
Zidovudine—Feeling abnormal—Etoposide—sarcoma	7.42e-05	0.00095	CcSEcCtD
Zidovudine—Diarrhoea—Mitoxantrone—sarcoma	7.4e-05	0.000948	CcSEcCtD
Zidovudine—Nausea—Dactinomycin—sarcoma	7.39e-05	0.000946	CcSEcCtD
Zidovudine—Agranulocytosis—Epirubicin—sarcoma	7.38e-05	0.000946	CcSEcCtD
Zidovudine—CYP3A4—liver—sarcoma	7.37e-05	0.00274	CbGeAlD
Zidovudine—Gastrointestinal pain—Etoposide—sarcoma	7.36e-05	0.000943	CcSEcCtD
Zidovudine—Dizziness—Vincristine—sarcoma	7.35e-05	0.000941	CcSEcCtD
Zidovudine—ABCC4—Platelet activation, signaling and aggregation—VEGFC—sarcoma	7.28e-05	0.00331	CbGpPWpGaD
Zidovudine—Stevens-Johnson syndrome—Doxorubicin—sarcoma	7.26e-05	0.00093	CcSEcCtD
Zidovudine—Neuropathy peripheral—Doxorubicin—sarcoma	7.17e-05	0.000919	CcSEcCtD
Zidovudine—Urticaria—Etoposide—sarcoma	7.15e-05	0.000916	CcSEcCtD
Zidovudine—Stomatitis—Doxorubicin—sarcoma	7.13e-05	0.000914	CcSEcCtD
Zidovudine—Jaundice—Doxorubicin—sarcoma	7.13e-05	0.000914	CcSEcCtD
Zidovudine—Rhinitis—Epirubicin—sarcoma	7.12e-05	0.000912	CcSEcCtD
Zidovudine—Body temperature increased—Etoposide—sarcoma	7.11e-05	0.000911	CcSEcCtD
Zidovudine—Abdominal pain—Etoposide—sarcoma	7.11e-05	0.000911	CcSEcCtD
Zidovudine—Hepatitis—Epirubicin—sarcoma	7.1e-05	0.00091	CcSEcCtD
Zidovudine—ABCB1—lymphoid tissue—sarcoma	7.09e-05	0.00263	CbGeAlD
Zidovudine—ALB—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	7.07e-05	0.00321	CbGpPWpGaD
Zidovudine—Vomiting—Vincristine—sarcoma	7.06e-05	0.000905	CcSEcCtD
Zidovudine—TERT—Disease—TLE1—sarcoma	7.05e-05	0.00321	CbGpPWpGaD
Zidovudine—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.05e-05	0.00321	CbGpPWpGaD
Zidovudine—Pharyngitis—Epirubicin—sarcoma	7.05e-05	0.000903	CcSEcCtD
Zidovudine—Sweating—Doxorubicin—sarcoma	7.02e-05	0.000899	CcSEcCtD
Zidovudine—Urinary tract disorder—Epirubicin—sarcoma	7.01e-05	0.000898	CcSEcCtD
Zidovudine—Rash—Vincristine—sarcoma	7e-05	0.000897	CcSEcCtD
Zidovudine—Dermatitis—Vincristine—sarcoma	7e-05	0.000897	CcSEcCtD
Zidovudine—Haematuria—Doxorubicin—sarcoma	6.98e-05	0.000894	CcSEcCtD
Zidovudine—Connective tissue disorder—Epirubicin—sarcoma	6.98e-05	0.000894	CcSEcCtD
Zidovudine—Urethral disorder—Epirubicin—sarcoma	6.96e-05	0.000892	CcSEcCtD
Zidovudine—Headache—Vincristine—sarcoma	6.96e-05	0.000892	CcSEcCtD
Zidovudine—TERT—TCF dependent signaling in response to WNT—CTNNB1—sarcoma	6.96e-05	0.00316	CbGpPWpGaD
Zidovudine—Hepatobiliary disease—Doxorubicin—sarcoma	6.92e-05	0.000887	CcSEcCtD
Zidovudine—TERT—TGF-beta Signaling Pathway—TP53—sarcoma	6.91e-05	0.00314	CbGpPWpGaD
Zidovudine—Epistaxis—Doxorubicin—sarcoma	6.9e-05	0.000884	CcSEcCtD
Zidovudine—Vomiting—Mitoxantrone—sarcoma	6.88e-05	0.000881	CcSEcCtD
Zidovudine—Sinusitis—Doxorubicin—sarcoma	6.87e-05	0.00088	CcSEcCtD
Zidovudine—Agranulocytosis—Doxorubicin—sarcoma	6.83e-05	0.000875	CcSEcCtD
Zidovudine—Rash—Mitoxantrone—sarcoma	6.82e-05	0.000874	CcSEcCtD
Zidovudine—Dermatitis—Mitoxantrone—sarcoma	6.82e-05	0.000873	CcSEcCtD
Zidovudine—Headache—Mitoxantrone—sarcoma	6.78e-05	0.000868	CcSEcCtD
Zidovudine—TERT—RNF mutants show enhanced WNT signaling and proliferation—CTNNB1—sarcoma	6.74e-05	0.00306	CbGpPWpGaD
Zidovudine—Erythema multiforme—Epirubicin—sarcoma	6.71e-05	0.00086	CcSEcCtD
Zidovudine—Nausea—Vincristine—sarcoma	6.6e-05	0.000845	CcSEcCtD
Zidovudine—Cardiac disorder—Epirubicin—sarcoma	6.59e-05	0.000844	CcSEcCtD
Zidovudine—Rhinitis—Doxorubicin—sarcoma	6.59e-05	0.000844	CcSEcCtD
Zidovudine—Hepatitis—Doxorubicin—sarcoma	6.57e-05	0.000842	CcSEcCtD
Zidovudine—Pharyngitis—Doxorubicin—sarcoma	6.52e-05	0.000835	CcSEcCtD
Zidovudine—Urinary tract disorder—Doxorubicin—sarcoma	6.49e-05	0.000831	CcSEcCtD
Zidovudine—Asthenia—Etoposide—sarcoma	6.46e-05	0.000827	CcSEcCtD
Zidovudine—Connective tissue disorder—Doxorubicin—sarcoma	6.46e-05	0.000827	CcSEcCtD
Zidovudine—ABCB1—bone marrow—sarcoma	6.45e-05	0.0024	CbGeAlD
Zidovudine—Urethral disorder—Doxorubicin—sarcoma	6.44e-05	0.000825	CcSEcCtD
Zidovudine—Nausea—Mitoxantrone—sarcoma	6.43e-05	0.000823	CcSEcCtD
Zidovudine—Mediastinal disorder—Epirubicin—sarcoma	6.4e-05	0.00082	CcSEcCtD
Zidovudine—ABCC4—Fluoropyrimidine Activity—TP53—sarcoma	6.39e-05	0.00291	CbGpPWpGaD
Zidovudine—Chills—Epirubicin—sarcoma	6.37e-05	0.000816	CcSEcCtD
Zidovudine—Pruritus—Etoposide—sarcoma	6.37e-05	0.000816	CcSEcCtD
Zidovudine—TERT—Disease—NPM1—sarcoma	6.36e-05	0.00289	CbGpPWpGaD
Zidovudine—ALB—Selenium Micronutrient Network—HBA1—sarcoma	6.33e-05	0.00288	CbGpPWpGaD
Zidovudine—TERT—Signaling by WNT in cancer—CTNNB1—sarcoma	6.26e-05	0.00284	CbGpPWpGaD
Zidovudine—Mental disorder—Epirubicin—sarcoma	6.22e-05	0.000797	CcSEcCtD
Zidovudine—Erythema multiforme—Doxorubicin—sarcoma	6.21e-05	0.000796	CcSEcCtD
Zidovudine—Erythema—Epirubicin—sarcoma	6.18e-05	0.000792	CcSEcCtD
Zidovudine—Malnutrition—Epirubicin—sarcoma	6.18e-05	0.000792	CcSEcCtD
Zidovudine—Diarrhoea—Etoposide—sarcoma	6.16e-05	0.000789	CcSEcCtD
Zidovudine—Cardiac disorder—Doxorubicin—sarcoma	6.1e-05	0.000781	CcSEcCtD
Zidovudine—Flatulence—Epirubicin—sarcoma	6.09e-05	0.00078	CcSEcCtD
Zidovudine—Tension—Epirubicin—sarcoma	6.07e-05	0.000777	CcSEcCtD
Zidovudine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—sarcoma	6.06e-05	0.00275	CbGpPWpGaD
Zidovudine—Dysgeusia—Epirubicin—sarcoma	6.05e-05	0.000775	CcSEcCtD
Zidovudine—Nervousness—Epirubicin—sarcoma	6e-05	0.000769	CcSEcCtD
Zidovudine—Back pain—Epirubicin—sarcoma	5.98e-05	0.000766	CcSEcCtD
Zidovudine—Dizziness—Etoposide—sarcoma	5.95e-05	0.000762	CcSEcCtD
Zidovudine—Muscle spasms—Epirubicin—sarcoma	5.94e-05	0.000761	CcSEcCtD
Zidovudine—Mediastinal disorder—Doxorubicin—sarcoma	5.92e-05	0.000759	CcSEcCtD
Zidovudine—Chills—Doxorubicin—sarcoma	5.89e-05	0.000755	CcSEcCtD
Zidovudine—Mental disorder—Doxorubicin—sarcoma	5.76e-05	0.000737	CcSEcCtD
Zidovudine—Ill-defined disorder—Epirubicin—sarcoma	5.73e-05	0.000735	CcSEcCtD
Zidovudine—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	5.73e-05	0.0026	CbGpPWpGaD
Zidovudine—Vomiting—Etoposide—sarcoma	5.72e-05	0.000733	CcSEcCtD
Zidovudine—Malnutrition—Doxorubicin—sarcoma	5.72e-05	0.000733	CcSEcCtD
Zidovudine—Erythema—Doxorubicin—sarcoma	5.72e-05	0.000733	CcSEcCtD
Zidovudine—Anaemia—Epirubicin—sarcoma	5.71e-05	0.000732	CcSEcCtD
Zidovudine—Rash—Etoposide—sarcoma	5.67e-05	0.000727	CcSEcCtD
Zidovudine—ABCG2—HIF-1-alpha transcription factor network—CREB1—sarcoma	5.67e-05	0.00258	CbGpPWpGaD
Zidovudine—Dermatitis—Etoposide—sarcoma	5.67e-05	0.000726	CcSEcCtD
Zidovudine—Headache—Etoposide—sarcoma	5.64e-05	0.000722	CcSEcCtD
Zidovudine—TERT—TCF dependent signaling in response to WNT—MYC—sarcoma	5.64e-05	0.00256	CbGpPWpGaD
Zidovudine—Flatulence—Doxorubicin—sarcoma	5.64e-05	0.000722	CcSEcCtD
Zidovudine—Tension—Doxorubicin—sarcoma	5.61e-05	0.000719	CcSEcCtD
Zidovudine—Dysgeusia—Doxorubicin—sarcoma	5.6e-05	0.000717	CcSEcCtD
Zidovudine—Malaise—Epirubicin—sarcoma	5.57e-05	0.000714	CcSEcCtD
Zidovudine—Nervousness—Doxorubicin—sarcoma	5.55e-05	0.000712	CcSEcCtD
Zidovudine—Vertigo—Epirubicin—sarcoma	5.55e-05	0.000711	CcSEcCtD
Zidovudine—Syncope—Epirubicin—sarcoma	5.54e-05	0.00071	CcSEcCtD
Zidovudine—Leukopenia—Epirubicin—sarcoma	5.53e-05	0.000709	CcSEcCtD
Zidovudine—Back pain—Doxorubicin—sarcoma	5.53e-05	0.000709	CcSEcCtD
Zidovudine—ABCB1—testis—sarcoma	5.52e-05	0.00205	CbGeAlD
Zidovudine—TERT—Disease—ENO2—sarcoma	5.51e-05	0.00251	CbGpPWpGaD
Zidovudine—Muscle spasms—Doxorubicin—sarcoma	5.5e-05	0.000704	CcSEcCtD
Zidovudine—TERT—RNF mutants show enhanced WNT signaling and proliferation—MYC—sarcoma	5.46e-05	0.00248	CbGpPWpGaD
Zidovudine—Loss of consciousness—Epirubicin—sarcoma	5.43e-05	0.000696	CcSEcCtD
Zidovudine—Cough—Epirubicin—sarcoma	5.39e-05	0.000691	CcSEcCtD
Zidovudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	5.36e-05	0.00244	CbGpPWpGaD
Zidovudine—Convulsion—Epirubicin—sarcoma	5.36e-05	0.000686	CcSEcCtD
Zidovudine—Nausea—Etoposide—sarcoma	5.35e-05	0.000685	CcSEcCtD
Zidovudine—Ill-defined disorder—Doxorubicin—sarcoma	5.31e-05	0.00068	CcSEcCtD
Zidovudine—Anaemia—Doxorubicin—sarcoma	5.29e-05	0.000677	CcSEcCtD
Zidovudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	5.27e-05	0.0024	CbGpPWpGaD
Zidovudine—Chest pain—Epirubicin—sarcoma	5.26e-05	0.000674	CcSEcCtD
Zidovudine—Arthralgia—Epirubicin—sarcoma	5.26e-05	0.000674	CcSEcCtD
Zidovudine—Myalgia—Epirubicin—sarcoma	5.26e-05	0.000674	CcSEcCtD
Zidovudine—Anxiety—Epirubicin—sarcoma	5.24e-05	0.000672	CcSEcCtD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	5.23e-05	0.00067	CcSEcCtD
Zidovudine—ABCB1—liver—sarcoma	5.22e-05	0.00194	CbGeAlD
Zidovudine—Discomfort—Epirubicin—sarcoma	5.2e-05	0.000666	CcSEcCtD
Zidovudine—Malaise—Doxorubicin—sarcoma	5.16e-05	0.000661	CcSEcCtD
Zidovudine—TERT—Signaling by Wnt—CTNNB1—sarcoma	5.16e-05	0.00234	CbGpPWpGaD
Zidovudine—Vertigo—Doxorubicin—sarcoma	5.14e-05	0.000658	CcSEcCtD
Zidovudine—Syncope—Doxorubicin—sarcoma	5.13e-05	0.000657	CcSEcCtD
Zidovudine—Leukopenia—Doxorubicin—sarcoma	5.12e-05	0.000656	CcSEcCtD
Zidovudine—ABCC4—Hemostasis—TEK—sarcoma	5.11e-05	0.00232	CbGpPWpGaD
Zidovudine—TK1—Metabolism—ENO2—sarcoma	5.1e-05	0.00232	CbGpPWpGaD
Zidovudine—Confusional state—Epirubicin—sarcoma	5.09e-05	0.000652	CcSEcCtD
Zidovudine—TK1—Metabolism—HBA1—sarcoma	5.07e-05	0.00231	CbGpPWpGaD
Zidovudine—TERT—Signaling by WNT in cancer—MYC—sarcoma	5.07e-05	0.0023	CbGpPWpGaD
Zidovudine—Oedema—Epirubicin—sarcoma	5.04e-05	0.000646	CcSEcCtD
Zidovudine—Anaphylactic shock—Epirubicin—sarcoma	5.04e-05	0.000646	CcSEcCtD
Zidovudine—Loss of consciousness—Doxorubicin—sarcoma	5.03e-05	0.000644	CcSEcCtD
Zidovudine—Cough—Doxorubicin—sarcoma	4.99e-05	0.000639	CcSEcCtD
Zidovudine—Shock—Epirubicin—sarcoma	4.96e-05	0.000636	CcSEcCtD
Zidovudine—Convulsion—Doxorubicin—sarcoma	4.95e-05	0.000635	CcSEcCtD
Zidovudine—Nervous system disorder—Epirubicin—sarcoma	4.95e-05	0.000634	CcSEcCtD
Zidovudine—Thrombocytopenia—Epirubicin—sarcoma	4.94e-05	0.000633	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—TLE1—sarcoma	4.94e-05	0.00225	CbGpPWpGaD
Zidovudine—Skin disorder—Epirubicin—sarcoma	4.9e-05	0.000628	CcSEcCtD
Zidovudine—Hyperhidrosis—Epirubicin—sarcoma	4.88e-05	0.000625	CcSEcCtD
Zidovudine—Myalgia—Doxorubicin—sarcoma	4.87e-05	0.000624	CcSEcCtD
Zidovudine—Arthralgia—Doxorubicin—sarcoma	4.87e-05	0.000624	CcSEcCtD
Zidovudine—Chest pain—Doxorubicin—sarcoma	4.87e-05	0.000624	CcSEcCtD
Zidovudine—Anxiety—Doxorubicin—sarcoma	4.85e-05	0.000622	CcSEcCtD
Zidovudine—ALB—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	4.84e-05	0.0022	CbGpPWpGaD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.84e-05	0.000619	CcSEcCtD
Zidovudine—Discomfort—Doxorubicin—sarcoma	4.81e-05	0.000616	CcSEcCtD
Zidovudine—Anorexia—Epirubicin—sarcoma	4.81e-05	0.000616	CcSEcCtD
Zidovudine—Confusional state—Doxorubicin—sarcoma	4.71e-05	0.000603	CcSEcCtD
Zidovudine—ABCG2—Fluoropyrimidine Activity—TP53—sarcoma	4.69e-05	0.00213	CbGpPWpGaD
Zidovudine—TERT—Disease—PLCG1—sarcoma	4.68e-05	0.00213	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—ANGPT2—sarcoma	4.67e-05	0.00212	CbGpPWpGaD
Zidovudine—Anaphylactic shock—Doxorubicin—sarcoma	4.67e-05	0.000598	CcSEcCtD
Zidovudine—Oedema—Doxorubicin—sarcoma	4.67e-05	0.000598	CcSEcCtD
Zidovudine—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	4.65e-05	0.00211	CbGpPWpGaD
Zidovudine—Musculoskeletal discomfort—Epirubicin—sarcoma	4.6e-05	0.000589	CcSEcCtD
Zidovudine—Shock—Doxorubicin—sarcoma	4.59e-05	0.000588	CcSEcCtD
Zidovudine—Nervous system disorder—Doxorubicin—sarcoma	4.58e-05	0.000586	CcSEcCtD
Zidovudine—Thrombocytopenia—Doxorubicin—sarcoma	4.57e-05	0.000585	CcSEcCtD
Zidovudine—Insomnia—Epirubicin—sarcoma	4.56e-05	0.000585	CcSEcCtD
Zidovudine—Skin disorder—Doxorubicin—sarcoma	4.53e-05	0.000581	CcSEcCtD
Zidovudine—Paraesthesia—Epirubicin—sarcoma	4.53e-05	0.00058	CcSEcCtD
Zidovudine—Hyperhidrosis—Doxorubicin—sarcoma	4.51e-05	0.000578	CcSEcCtD
Zidovudine—Dyspnoea—Epirubicin—sarcoma	4.5e-05	0.000576	CcSEcCtD
Zidovudine—TERT—Disease—CXCR4—sarcoma	4.49e-05	0.00204	CbGpPWpGaD
Zidovudine—Somnolence—Epirubicin—sarcoma	4.48e-05	0.000575	CcSEcCtD
Zidovudine—Anorexia—Doxorubicin—sarcoma	4.45e-05	0.00057	CcSEcCtD
Zidovudine—Dyspepsia—Epirubicin—sarcoma	4.44e-05	0.000569	CcSEcCtD
Zidovudine—Decreased appetite—Epirubicin—sarcoma	4.39e-05	0.000562	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Epirubicin—sarcoma	4.35e-05	0.000558	CcSEcCtD
Zidovudine—Fatigue—Epirubicin—sarcoma	4.35e-05	0.000557	CcSEcCtD
Zidovudine—TK1—Metabolism—PLCG1—sarcoma	4.33e-05	0.00197	CbGpPWpGaD
Zidovudine—Constipation—Epirubicin—sarcoma	4.31e-05	0.000553	CcSEcCtD
Zidovudine—Pain—Epirubicin—sarcoma	4.31e-05	0.000553	CcSEcCtD
Zidovudine—CYP2A6—Fluoropyrimidine Activity—TP53—sarcoma	4.26e-05	0.00194	CbGpPWpGaD
Zidovudine—Musculoskeletal discomfort—Doxorubicin—sarcoma	4.25e-05	0.000545	CcSEcCtD
Zidovudine—Insomnia—Doxorubicin—sarcoma	4.22e-05	0.000541	CcSEcCtD
Zidovudine—Paraesthesia—Doxorubicin—sarcoma	4.19e-05	0.000537	CcSEcCtD
Zidovudine—TERT—Signaling by Wnt—MYC—sarcoma	4.18e-05	0.0019	CbGpPWpGaD
Zidovudine—ABCC4—Platelet degranulation—VEGFA—sarcoma	4.17e-05	0.00189	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—VEGFC—sarcoma	4.17e-05	0.00189	CbGpPWpGaD
Zidovudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	4.16e-05	0.00189	CbGpPWpGaD
Zidovudine—Dyspnoea—Doxorubicin—sarcoma	4.16e-05	0.000533	CcSEcCtD
Zidovudine—Feeling abnormal—Epirubicin—sarcoma	4.16e-05	0.000533	CcSEcCtD
Zidovudine—Somnolence—Doxorubicin—sarcoma	4.15e-05	0.000532	CcSEcCtD
Zidovudine—Gastrointestinal pain—Epirubicin—sarcoma	4.12e-05	0.000528	CcSEcCtD
Zidovudine—Dyspepsia—Doxorubicin—sarcoma	4.11e-05	0.000526	CcSEcCtD
Zidovudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	4.09e-05	0.00186	CbGpPWpGaD
Zidovudine—ABCG2—HIF-1-alpha transcription factor network—JUN—sarcoma	4.08e-05	0.00185	CbGpPWpGaD
Zidovudine—Decreased appetite—Doxorubicin—sarcoma	4.06e-05	0.00052	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Doxorubicin—sarcoma	4.03e-05	0.000516	CcSEcCtD
Zidovudine—Fatigue—Doxorubicin—sarcoma	4.02e-05	0.000516	CcSEcCtD
Zidovudine—Urticaria—Epirubicin—sarcoma	4.01e-05	0.000513	CcSEcCtD
Zidovudine—ABCB1—lymph node—sarcoma	4e-05	0.00149	CbGeAlD
Zidovudine—Constipation—Doxorubicin—sarcoma	3.99e-05	0.000511	CcSEcCtD
Zidovudine—Pain—Doxorubicin—sarcoma	3.99e-05	0.000511	CcSEcCtD
Zidovudine—Body temperature increased—Epirubicin—sarcoma	3.99e-05	0.000511	CcSEcCtD
Zidovudine—Abdominal pain—Epirubicin—sarcoma	3.99e-05	0.000511	CcSEcCtD
Zidovudine—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	3.97e-05	0.0018	CbGpPWpGaD
Zidovudine—TERT—Cell Cycle—MDM2—sarcoma	3.88e-05	0.00176	CbGpPWpGaD
Zidovudine—Feeling abnormal—Doxorubicin—sarcoma	3.85e-05	0.000493	CcSEcCtD
Zidovudine—Gastrointestinal pain—Doxorubicin—sarcoma	3.82e-05	0.000489	CcSEcCtD
Zidovudine—ABCC4—Hemostasis—VEGFC—sarcoma	3.75e-05	0.0017	CbGpPWpGaD
Zidovudine—Urticaria—Doxorubicin—sarcoma	3.71e-05	0.000475	CcSEcCtD
Zidovudine—Abdominal pain—Doxorubicin—sarcoma	3.69e-05	0.000473	CcSEcCtD
Zidovudine—Body temperature increased—Doxorubicin—sarcoma	3.69e-05	0.000473	CcSEcCtD
Zidovudine—Asthenia—Epirubicin—sarcoma	3.62e-05	0.000464	CcSEcCtD
Zidovudine—ABCB1—Allograft Rejection—PDGFRA—sarcoma	3.6e-05	0.00164	CbGpPWpGaD
Zidovudine—Pruritus—Epirubicin—sarcoma	3.57e-05	0.000457	CcSEcCtD
Zidovudine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—sarcoma	3.56e-05	0.00162	CbGpPWpGaD
Zidovudine—Diarrhoea—Epirubicin—sarcoma	3.45e-05	0.000442	CcSEcCtD
Zidovudine—TERT—Cell Cycle—CCND1—sarcoma	3.38e-05	0.00154	CbGpPWpGaD
Zidovudine—Asthenia—Doxorubicin—sarcoma	3.35e-05	0.000429	CcSEcCtD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	3.35e-05	0.00152	CbGpPWpGaD
Zidovudine—Dizziness—Epirubicin—sarcoma	3.34e-05	0.000427	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—FLT1—sarcoma	3.33e-05	0.00151	CbGpPWpGaD
Zidovudine—TERT—Disease—FOXO1—sarcoma	3.32e-05	0.00151	CbGpPWpGaD
Zidovudine—TERT—Disease—PDGFRB—sarcoma	3.31e-05	0.00151	CbGpPWpGaD
Zidovudine—Pruritus—Doxorubicin—sarcoma	3.3e-05	0.000423	CcSEcCtD
Zidovudine—ALB—Platelet activation, signaling and aggregation—VEGFC—sarcoma	3.29e-05	0.0015	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—PLCG1—sarcoma	3.27e-05	0.00149	CbGpPWpGaD
Zidovudine—TERT—Disease—PDGFRA—sarcoma	3.26e-05	0.00148	CbGpPWpGaD
Zidovudine—Vomiting—Epirubicin—sarcoma	3.21e-05	0.000411	CcSEcCtD
Zidovudine—Diarrhoea—Doxorubicin—sarcoma	3.19e-05	0.000409	CcSEcCtD
Zidovudine—Rash—Epirubicin—sarcoma	3.18e-05	0.000407	CcSEcCtD
Zidovudine—Dermatitis—Epirubicin—sarcoma	3.18e-05	0.000407	CcSEcCtD
Zidovudine—Headache—Epirubicin—sarcoma	3.16e-05	0.000405	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—CXCR4—sarcoma	3.15e-05	0.00143	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—ATF1—sarcoma	3.11e-05	0.00141	CbGpPWpGaD
Zidovudine—ABCC5—Disease—TLE1—sarcoma	3.1e-05	0.00141	CbGpPWpGaD
Zidovudine—Dizziness—Doxorubicin—sarcoma	3.09e-05	0.000395	CcSEcCtD
Zidovudine—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	3.07e-05	0.00139	CbGpPWpGaD
Zidovudine—ABCC4—Ectoderm Differentiation—CTNNB1—sarcoma	3.06e-05	0.00139	CbGpPWpGaD
Zidovudine—Nausea—Epirubicin—sarcoma	3e-05	0.000384	CcSEcCtD
Zidovudine—Vomiting—Doxorubicin—sarcoma	2.97e-05	0.00038	CcSEcCtD
Zidovudine—ABCC4—Hemostasis—PLCG1—sarcoma	2.95e-05	0.00134	CbGpPWpGaD
Zidovudine—Rash—Doxorubicin—sarcoma	2.94e-05	0.000377	CcSEcCtD
Zidovudine—Dermatitis—Doxorubicin—sarcoma	2.94e-05	0.000377	CcSEcCtD
Zidovudine—Headache—Doxorubicin—sarcoma	2.92e-05	0.000375	CcSEcCtD
Zidovudine—ABCC5—Disease—NPM1—sarcoma	2.8e-05	0.00127	CbGpPWpGaD
Zidovudine—Nausea—Doxorubicin—sarcoma	2.77e-05	0.000355	CcSEcCtD
Zidovudine—TERT—Cell Cycle—MYC—sarcoma	2.71e-05	0.00123	CbGpPWpGaD
Zidovudine—ALB—Folate Metabolism—IL2—sarcoma	2.59e-05	0.00118	CbGpPWpGaD
Zidovudine—TERT—Disease—KIT—sarcoma	2.53e-05	0.00115	CbGpPWpGaD
Zidovudine—ABCC4—Ectoderm Differentiation—MYC—sarcoma	2.48e-05	0.00113	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—IGF1R—sarcoma	2.44e-05	0.00111	CbGpPWpGaD
Zidovudine—ABCC5—Disease—ENO2—sarcoma	2.43e-05	0.0011	CbGpPWpGaD
Zidovudine—TERT—Disease—CREB1—sarcoma	2.41e-05	0.00109	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—FOXO1—sarcoma	2.32e-05	0.00106	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—PDGFRB—sarcoma	2.32e-05	0.00105	CbGpPWpGaD
Zidovudine—SLC22A2—Transmission across Chemical Synapses—CREB1—sarcoma	2.31e-05	0.00105	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—TEK—sarcoma	2.31e-05	0.00105	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—PDGFRA—sarcoma	2.28e-05	0.00104	CbGpPWpGaD
Zidovudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	2.25e-05	0.00102	CbGpPWpGaD
Zidovudine—TERT—Cell Cycle—TP53—sarcoma	2.23e-05	0.00101	CbGpPWpGaD
Zidovudine—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	2.21e-05	0.001	CbGpPWpGaD
Zidovudine—ABCC4—Platelet activation, signaling and aggregation—IL2—sarcoma	2.18e-05	0.000989	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—ANGPT2—sarcoma	2.11e-05	0.000961	CbGpPWpGaD
Zidovudine—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	2.09e-05	0.000949	CbGpPWpGaD
Zidovudine—ABCC5—Disease—PLCG1—sarcoma	2.06e-05	0.000936	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—ENO2—sarcoma	2.03e-05	0.000924	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—HBA1—sarcoma	2.02e-05	0.000918	CbGpPWpGaD
Zidovudine—TERT—Disease—MDM2—sarcoma	1.99e-05	0.000905	CbGpPWpGaD
Zidovudine—ABCC5—Disease—CXCR4—sarcoma	1.98e-05	0.000899	CbGpPWpGaD
Zidovudine—ABCB1—Allograft Rejection—IL2—sarcoma	1.96e-05	0.000893	CbGpPWpGaD
Zidovudine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	1.93e-05	0.000876	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—KDR—sarcoma	1.92e-05	0.000874	CbGpPWpGaD
Zidovudine—SLC22A2—Transmission across Chemical Synapses—MDM2—sarcoma	1.91e-05	0.00087	CbGpPWpGaD
Zidovudine—ABCC4—Platelet activation, signaling and aggregation—SRC—sarcoma	1.9e-05	0.000863	CbGpPWpGaD
Zidovudine—ALB—Platelet degranulation—VEGFA—sarcoma	1.89e-05	0.000857	CbGpPWpGaD
Zidovudine—ABCC4—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.85e-05	0.00084	CbGpPWpGaD
Zidovudine—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	1.8e-05	0.000817	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	1.78e-05	0.000807	CbGpPWpGaD
Zidovudine—SLC22A2—Neuronal System—CREB1—sarcoma	1.77e-05	0.000806	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—KIT—sarcoma	1.77e-05	0.000805	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—PLCG1—sarcoma	1.72e-05	0.000784	CbGpPWpGaD
Zidovudine—TERT—Disease—CTNNB1—sarcoma	1.72e-05	0.000781	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—VEGFC—sarcoma	1.7e-05	0.000771	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—CREB1—sarcoma	1.69e-05	0.000766	CbGpPWpGaD
Zidovudine—ABCB1—Allograft Rejection—VEGFA—sarcoma	1.67e-05	0.000759	CbGpPWpGaD
Zidovudine—ALB—Folate Metabolism—TP53—sarcoma	1.66e-05	0.000756	CbGpPWpGaD
Zidovudine—TERT—Disease—SRC—sarcoma	1.55e-05	0.000706	CbGpPWpGaD
Zidovudine—UGT2B7—Metabolism—ENO2—sarcoma	1.5e-05	0.000681	CbGpPWpGaD
Zidovudine—TERT—Disease—NRAS—sarcoma	1.49e-05	0.000679	CbGpPWpGaD
Zidovudine—UGT2B7—Metabolism—HBA1—sarcoma	1.49e-05	0.000677	CbGpPWpGaD
Zidovudine—SLC22A2—Neuronal System—MDM2—sarcoma	1.47e-05	0.000667	CbGpPWpGaD
Zidovudine—ABCC5—Disease—FOXO1—sarcoma	1.46e-05	0.000664	CbGpPWpGaD
Zidovudine—ABCC5—Disease—PDGFRB—sarcoma	1.46e-05	0.000663	CbGpPWpGaD
Zidovudine—ABCC5—Disease—PDGFRA—sarcoma	1.44e-05	0.000652	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—MDM2—sarcoma	1.39e-05	0.000634	CbGpPWpGaD
Zidovudine—TERT—Disease—MYC—sarcoma	1.39e-05	0.000632	CbGpPWpGaD
Zidovudine—TERT—Disease—EGFR—sarcoma	1.36e-05	0.000618	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—PLCG1—sarcoma	1.33e-05	0.000606	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	1.31e-05	0.000596	CbGpPWpGaD
Zidovudine—TERT—Disease—KRAS—sarcoma	1.29e-05	0.000584	CbGpPWpGaD
Zidovudine—UGT2B7—Metabolism—PLCG1—sarcoma	1.27e-05	0.000578	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—IL2—sarcoma	1.25e-05	0.000566	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—CCND1—sarcoma	1.21e-05	0.000552	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—JUN—sarcoma	1.21e-05	0.000551	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—CTNNB1—sarcoma	1.2e-05	0.000547	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—IL2—sarcoma	1.12e-05	0.00051	CbGpPWpGaD
Zidovudine—ABCC5—Disease—KIT—sarcoma	1.11e-05	0.000506	CbGpPWpGaD
Zidovudine—TERT—Disease—HRAS—sarcoma	1.09e-05	0.000497	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—SRC—sarcoma	1.09e-05	0.000494	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	1.08e-05	0.000493	CbGpPWpGaD
Zidovudine—ABCC5—Disease—CREB1—sarcoma	1.06e-05	0.000482	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—VEGFA—sarcoma	1.06e-05	0.000481	CbGpPWpGaD
Zidovudine—SLC22A2—Transmission across Chemical Synapses—HRAS—sarcoma	1.05e-05	0.000477	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—NRAS—sarcoma	1.05e-05	0.000475	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—ENO2—sarcoma	1.03e-05	0.000469	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—HBA1—sarcoma	1.03e-05	0.000466	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—ENO2—sarcoma	1.02e-05	0.000465	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—HBA1—sarcoma	1.02e-05	0.000462	CbGpPWpGaD
Zidovudine—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	9.84e-06	0.000447	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—SRC—sarcoma	9.78e-06	0.000445	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—MYC—sarcoma	9.74e-06	0.000443	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—VEGFA—sarcoma	9.53e-06	0.000433	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—EGFR—sarcoma	9.53e-06	0.000433	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	9.45e-06	0.000429	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	9.43e-06	0.000429	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—NRAS—sarcoma	9.41e-06	0.000428	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—ENO2—sarcoma	9.38e-06	0.000426	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	9.36e-06	0.000425	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—HBA1—sarcoma	9.32e-06	0.000424	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—KRAS—sarcoma	9e-06	0.000409	CbGpPWpGaD
Zidovudine—ABCC5—Disease—MDM2—sarcoma	8.76e-06	0.000398	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—PLCG1—sarcoma	8.76e-06	0.000398	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—PLCG1—sarcoma	8.67e-06	0.000394	CbGpPWpGaD
Zidovudine—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	8.59e-06	0.00039	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	8.46e-06	0.000384	CbGpPWpGaD
Zidovudine—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	8.36e-06	0.00038	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	8.24e-06	0.000374	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—KRAS—sarcoma	8.1e-06	0.000368	CbGpPWpGaD
Zidovudine—SLC22A2—Neuronal System—HRAS—sarcoma	8.05e-06	0.000366	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—TP53—sarcoma	8e-06	0.000364	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—PLCG1—sarcoma	7.96e-06	0.000362	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—HRAS—sarcoma	7.65e-06	0.000348	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	7.58e-06	0.000344	CbGpPWpGaD
Zidovudine—ABCC5—Disease—CTNNB1—sarcoma	7.56e-06	0.000344	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	7.41e-06	0.000337	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—TP53—sarcoma	7.2e-06	0.000327	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	7e-06	0.000318	CbGpPWpGaD
Zidovudine—ABCC4—Hemostasis—HRAS—sarcoma	6.89e-06	0.000313	CbGpPWpGaD
Zidovudine—ABCC5—Disease—SRC—sarcoma	6.83e-06	0.000311	CbGpPWpGaD
Zidovudine—ABCC5—Disease—NRAS—sarcoma	6.57e-06	0.000299	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—ENO2—sarcoma	6.41e-06	0.000291	CbGpPWpGaD
Zidovudine—ALB—Metabolism—ENO2—sarcoma	6.37e-06	0.00029	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—HBA1—sarcoma	6.37e-06	0.000289	CbGpPWpGaD
Zidovudine—ALB—Metabolism—HBA1—sarcoma	6.33e-06	0.000288	CbGpPWpGaD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	6.22e-06	0.000283	CbGpPWpGaD
Zidovudine—ABCC5—Disease—MYC—sarcoma	6.12e-06	0.000278	CbGpPWpGaD
Zidovudine—ABCC5—Disease—EGFR—sarcoma	5.99e-06	0.000272	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—ENO2—sarcoma	5.72e-06	0.00026	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—HBA1—sarcoma	5.68e-06	0.000258	CbGpPWpGaD
Zidovudine—ABCC5—Disease—KRAS—sarcoma	5.66e-06	0.000257	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—ENO2—sarcoma	5.58e-06	0.000254	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—HBA1—sarcoma	5.55e-06	0.000252	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—PLCG1—sarcoma	5.44e-06	0.000247	CbGpPWpGaD
Zidovudine—ALB—Metabolism—PLCG1—sarcoma	5.41e-06	0.000246	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—ENO2—sarcoma	5.22e-06	0.000237	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—HBA1—sarcoma	5.18e-06	0.000236	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—IL2—sarcoma	5.07e-06	0.000231	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—PLCG1—sarcoma	4.85e-06	0.000221	CbGpPWpGaD
Zidovudine—ABCC5—Disease—HRAS—sarcoma	4.81e-06	0.000219	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—PLCG1—sarcoma	4.74e-06	0.000215	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—SRC—sarcoma	4.43e-06	0.000201	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—PLCG1—sarcoma	4.43e-06	0.000201	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—VEGFA—sarcoma	4.31e-06	0.000196	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—NRAS—sarcoma	4.26e-06	0.000194	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—KRAS—sarcoma	3.67e-06	0.000167	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—ENO2—sarcoma	3.44e-06	0.000156	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—HBA1—sarcoma	3.42e-06	0.000155	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—TP53—sarcoma	3.26e-06	0.000148	CbGpPWpGaD
Zidovudine—ALB—Hemostasis—HRAS—sarcoma	3.12e-06	0.000142	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—PLCG1—sarcoma	2.92e-06	0.000133	CbGpPWpGaD
